A Phase III trial (ASCENT-04/KEYNOTE-D19) has shown that the Trodelvy Keytruda combination improves progression-free survival over Keytruda plus chemotherapy in previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC). ...